文献速递泌尿男性生殖肿瘤

纳武利尤单抗联合伊匹木单抗对比舒尼替尼治疗晚期肾细胞癌的患者报告结局(CheckMate 214):一项随机、3期试验

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-01-15

在CheckMate 214 3期随机试验中,中/高危晚期肾细胞癌患者接受纳武利尤单抗联合伊匹木单抗或舒尼替尼治疗。至第103周,联合组FKSI-19总分和FACT-G总分较基线改善,而舒尼替尼组恶化,联合组还降低了FKSI-19总分、FACT-G总分和EQ-5D-3L VAS评分及英国效用评分的恶化风险。

要点

  • 至第103周,纳武利尤单抗联合伊匹木单抗组FKSI-19总分较基线平均变化为4.00,舒尼替尼组为-3.14(p<0.0001)。
  • 至第103周,联合组FACT-G总分较基线平均变化为4.77,舒尼替尼组为-4.32(p=0.0005)。
  • 联合组降低FKSI-19总分恶化风险(HR 0.54;95% CI 0.46-0.63)。

核心结论

  • 在中/高危晚期肾细胞癌患者中,纳武利尤单抗联合伊匹木单抗比舒尼替尼带来更少症状和更好的健康相关生活质量。
  • 这些结果提示纳武利尤单抗联合伊匹木单抗优于舒尼替尼的疗效伴随健康相关生活质量改善的额外获益。

研究设计与样本

  • 3期、随机、对照、开放标签CheckMate 214试验,自28个国家175家医院和癌症中心招募≥18岁既往未治疗、伴透明细胞成分的晚期或转移性肾细胞癌患者。
  • 患者按风险状态分为有利、中危和低危亚组,按1:1随机分配至纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg每3周共4次后纳武利尤单抗3 mg/kg每2周,或舒尼替尼50 mg/天每6周周期中用4周。
  • 随机采用区组大小4,按风险状态和地理区域分层;患者报告结局采用FKSI-19、FACT-G和EQ-5D-3L工具评估,为探索性终点。
  • 2014年10月16日至2016年2月23日筛查1390例患者,1096例(79%)随机分配,其中847例(77%)为中/低危并随机分配至联合组(n=425)或舒尼替尼组(n=422)。
  • 中位随访25.2个月(IQR 23.0-27.4);试验注册号NCT02231749,仍在进行但已停止招募。

主要发现

  • 至第103周,FKSI-19总分较基线平均变化联合组为4.00(95% CI 1.91-6.09),舒尼替尼组为-3.14(95% CI -6.03至-0.25),p<0.0001。
  • 至第103周,FACT-G总分较基线平均变化联合组为4.77(95% CI 1.73-7.82),舒尼替尼组为-4.32(95% CI -8.54至-0.11),p=0.0005。
  • FKSI-19五个域中四个域(疾病相关症状、躯体疾病相关症状、治疗副作用和功能健康)以及FACT-G躯体和功能健康域也见显著差异。
  • 第103周EQ-5D-3L VAS评分较基线平均变化联合组为10.07(95% CI 4.35-15.80),舒尼替尼组为6.40(95% CI -1.36至14.16),p=0.45,两组无显著差异。
  • 与舒尼替尼相比,联合组降低FKSI-19总分恶化风险(HR 0.54;95% CI 0.46-0.63)、FACT-G总分恶化风险(HR 0.63;95% CI 0.52-0.75)、EQ-5D-3L VAS评分恶化风险(HR 0.75;95% CI 0.63-0.89)和英国效用评分恶化风险(HR 0.67;95% CI 0.57-0.80)。

关键数值与推荐

  • FKSI-19总分较基线变化:联合组4.00(95% CI 1.91-6.09) vs 舒尼替尼组-3.14(95% CI -6.03至-0.25),p<0.0001。
  • FACT-G总分较基线变化:联合组4.77(95% CI 1.73-7.82) vs 舒尼替尼组-4.32(95% CI -8.54至-0.11),p=0.0005。
  • EQ-5D-3L VAS评分较基线变化:联合组10.07(95% CI 4.35-15.80) vs 舒尼替尼组6.40(95% CI -1.36至14.16),p=0.45。
  • FKSI-19总分恶化HR 0.54(95% CI 0.46-0.63);FACT-G总分恶化HR 0.63(95% CI 0.52-0.75)。
  • EQ-5D-3L VAS评分恶化HR 0.75(95% CI 0.63-0.89);英国效用评分恶化HR 0.67(95% CI 0.57-0.80)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为,在中/高危晚期肾细胞癌患者中,纳武利尤单抗联合伊匹木单抗比舒尼替尼带来更少症状和更好的健康相关生活质量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the ongoing phase 3, CheckMate 214 trial, nivolumab plus ipilimumab improved overall survival compared with sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma. We aimed to assess whether health-related quality of life (HRQoL) could be used to further describe the benefit-risk profile of nivolumab plus ipilimumab versus sunitinib. METHODS: In the phase 3, randomised, controlled, CheckMate 214 trial, patients aged 18 years and older with previously untreated, advanced or metastatic renal cell carcinoma with a clear-cell component were recruited from 175 hospitals and cancer centres in 28 countries. Patients were categorised by risk status into favourable, intermediate, and poor risk subgroups and randomly assigned (1:1) to open-label nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab 3 mg/kg every 2 weeks, or sunitinib 50 mg/day for 4 weeks of each 6-week cycle. Randomisation was done with a block size of four and stratified by risk status and geographical region. Patient-reported outcomes (PROs) were assessed using the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (FKSI-19), Functional Assessment of Cancer Therapy-General (FACT-G), and EuroQol five dimensional three level (EQ-5D-3L) instruments. The coprimary endpoints of the trial, reported previously, were overall survival, progression-free survival, and the proportion of patients who had an objective response in those categorised as at intermediate or poor risk. PROs in all randomised participants were assessed as an exploratory endpoint; here we report this exploratory endpoint. This study is registered with ClinicalTrials.gov, number NCT02231749, and is ongoing but is now closed to recruitment. FINDINGS: Between Oct 16, 2014, and Feb 23, 2016, of 1390 patients screened, 1096 (79%) were randomly assigned to treatment, of whom 847 (77%) were at intermediate or poor risk and randomly assigned to nivolumab plus ipilimumab (n=425) or sunitinib (n=422). Median follow-up was 25·2 months (IQR 23·0-27·4). PROs were more favourable with nivolumab plus ipilimumab than sunitinib throughout the first 103 weeks after baseline, with mean change from baseline at week 103 for FKSI-19 total score being 4·00 (95% CI 1·91 to 6·09) for nivolumab plus ipilimumab versus -3·14 (-6·03 to -0·25) for sunitinib (p<0·0001), and for FACT-G total score being 4·77 (1·73 to 7·82) for nivolumab plus ipilimumab versus -4·32 (-8·54 to -0·11) for sunitinib (p=0·0005). Significant differences were also seen for four of five FKSI-19 domains (disease-related symptoms, physical disease-related symptoms, treatment side-effects, and functional wellbeing) and FACT-G physical and functional wellbeing domains. However, there was no significant difference between the treatment groups at week 103 in EQ-5D-3L visual analogue rating scale (VAS) scores, with mean change from baseline to week 103 of 10·07 (95% CI 4·35 to 15·80) for nivolumab plus ipilimumab and 6·40 (-1·36 to 14·16) for sunitinib (p=0·45). Compared with sunitinib, nivolumab plus ipilimumab reduced risk of deterioration in FKSI-19 total score (hazard ratio [HR] 0·54; 95% CI 0·46-0·63), FACT-G total score (0·63, 0·52-0·75), and EQ-5D-3L VAS score (HR 0·75, 95% CI 0·63-0·89) and UK utility scores (0·67, 0·57-0·80). INTERPRETATION: Nivolumab plus ipilimumab leads to fewer symptoms and better HRQoL than sunitinib in patients at intermediate or poor risk with advanced renal cell carcinoma. These results suggest that the superior efficacy of nivolumab plus ipilimumab over sunitinib comes with the additional benefit of improved HRQoL. FUNDING: Bristol-Myers Squibb and ONO Pharmaceutical.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Cella D, Grünwald V, Escudier B, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019. PMID: 30658932. doi:10.1016/S1470-2045(18)30778-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。